OR-1855

OR-1855, an active metabolite of Levosimendan (HY-14286), has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD(P)H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation^[1][2][3]. In Vitro:OR-1855 (10 μM, 30 min pretreatment) can significantly inhibit IL-1β-induced ROS production in HUVECs and can reduce IL-1β-induced NAD(P)H oxidase-dependent superoxide anion production^[3].
OR-1855 (10 μM, 30 min pretreatment) can significantly inhibit IL-1β-induced phosphorylation p38 MAPK, ERK1/2, and JNK in HUVECs, and simultaneously reduce the phosphorylation level of c-Jun^[3].
OR-1855 (10 μM, 30 min pretreatment) has no significant effect on the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) induced by IL-1β, nor does it reduce IL-1β-induced interleukin-6 (IL-6) mRNA expression, which is different from the anti-inflammatory effect of levosimendan^[3].